Related Experiment Video
Updated: May 26, 2026
08:53
Randomized, Triple-Blind, and Parallel-Controlled Trial of Transcranial Direct Current Stimulation for Cognitive Rehabilitation after Stroke
Published on: June 6, 2025
Smoking cessation intervention after ischemic stroke or transient ischemic attack. A randomized controlled pilot
Nicole Brunner Frandsen1, Margit Sørensen, Tanja Kirstine Hyldahl
1Department of Neurology, Odense University Hospital, Odense, Denmark. nbrunner80@hotmail.com
Summary
Intensive smoking cessation interventions showed no significant benefit over minimal interventions for patients who experienced stroke or transient ischemic attack (TIA). Further research is needed to identify factors influencing cessation success in this population.
Area of Science:
- Neurology
- Public Health
- Addiction Medicine
Background:
- Smoking cessation is crucial for secondary stroke prevention.
- Efficacy of interventions post-stroke or TIA remains understudied.
Purpose of the Study:
- To evaluate the efficacy of intensive versus minimal smoking cessation interventions in stroke/TIA patients.
- To determine smoking cessation rates at 6 months post-intervention.
Main Methods:
- Pilot study with 94 smokers (aged <76) randomized to minimal or intensive intervention.
- Intensive group received additional outpatient sessions, telephone counseling, and nicotine replacement therapy.
- Cessation verified by self-report and exhaled carbon monoxide (CO) at 6 months.
Main Results:
- 6-month self-reported cessation rates: 37.8% (minimal) vs. 42.9% (intensive).
- CO-verified cessation rates: 28.9% (minimal) vs. 32.7% (intensive).
- No statistically significant difference between intervention groups (p = .69).
Conclusions:
- Moderate smoking cessation rates observed, comparable to other studies.
- Intensive intervention did not outperform minimal intervention.
- Factors beyond intervention intensity likely influence smoking cessation success after stroke/TIA.
Related Concept Videos
01:28Acute Coronary Syndrome IV: Interprofessional Care
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
01:15Ischemic Stroke l: Introduction
Ischemic stroke is an acute cerebrovascular condition in which blood flow to a brain region is suddenly interrupted, leading to tissue infarction. Neurons depend on continuous oxygen and glucose supply, so even brief reductions in perfusion cause energy failure, ionic imbalance, and irreversible injury. Ischemic strokes are classified into thrombotic and embolic types based on their underlying mechanisms.Thrombotic MechanismsThrombotic stroke develops when a clot forms within a cerebral artery.
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:26Transient Ischemic Attack l: Introduction
A transient ischemic attack (TIA) is a brief episode of neurological dysfunction caused by a temporary, focal reduction in cerebral blood flow. Although symptoms resemble those of an ischemic stroke, the interruption in perfusion is short-lived and does not cause permanent infarction. TIAs are clinically important because they often serve as early warning events for future stroke.Mechanisms of Transient Cerebral IschemiaTransient cerebral ischemia may arise through several mechanisms. One...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...